Table of Contents

NOTE 15:

OTHER RELATED PARTY TRANSACTIONS

Consulting Agreement On March 26, 2009, we entered into a consulting agreement with our former chief executive offer and current Director. For the years ended December 31, 2010 and 2009, we incurred $24,000 and $189,000 in general and administrative expenses under the consultant arrangement, respectively. At December 31, 2009, we owed the consultant $377,000, which included amounts owed for severance of $366,000. On February 1, 2010, we re-hired the consultant as our chief executive officer. There was no amount owed to our chief executive officer at December 31, 2010. On September 14, 2009, we entered into a consulting agreement with our former Vice President and Chief Science Officer. For the year ended December 31, 2010 and 2009, we incurred $48,000 and $11,000 in research and development expenses under the consulting arrangement, respectively. On February 1, 2010, this consulting agreement was terminated when we re-hired our Senior Vice President and Chief Science Officer. NOTE 16: UNAUDITED QUARTERLY FINANCIAL INFORMATION

Certain unaudited quarterly financial information for the years ended December 31, 2010 and 2009 is presented below:
2010 Quarter Ended (In thousands, except per share data) March 31 June 30 September 30 December 31

Revenue Gross Profit Net loss Loss per share - basic and diluted

73 73 (11,586) (1.14)
March 31

344 332 (698) (0.07)

June 30

413 400 (2,736) (0.26)

September 30

345 282 (4,014) (0.38)

December 31

2009 Quarter Ended

Revenue Gross Profit Net loss Loss per share - basic and diluted NOTE 17: SUBSEQUENT EVENTS

(2,815) (0.44)

(1,793) (0.28)

(11,015) (1.72)

(6,425) (0.86)

On November 2, 2010, we received notice of an award of two grants for the aggregate sum of $489,000 under the Internal Revenue Service Qualifying Therapeutic Discovery Projects Grant Program for our OVA2 and PAD programs. These grants were included in other income for the year ended December 31, 2010 and cash equal to the total amount awarded was received by us on February 3, 2011. On February 18, 2011 we completed a follow-on public offering sale of 4,000,000 shares of our common stock in an underwritten public offering at a price of $5.45 per share. We expect net proceeds of the offering will be approximately $20,200,000 after deducting underwriting discounts and expected offering expenses. Roth Capital Partners acted as the sole manager of the offering. The underwriter has been granted a 30-day option to purchase up to 500,000 additional shares from the Company and 100,000 shares from a selling stockholder to cover over-allotments, if any. F-37